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Removal of middle molecules and protein-bound solutes by
peritoneal dialysis and relation with uremic symptoms.
Background. Current guidelines for peritoneal dialysis ade-
quacy are based on kinetics of small water-soluble molecules
and do not consider the role of other compounds such as mid-
dle molecules and protein-bound solutes. Information on the
elimination characteristics of the latter solutes by peritoneal
dialysis is limited. Moreover, their relation with uremic symp-
toms remains unclear. The aim of the present study was (1) to
investigate the relative contribution of residual renal function
to the overall clearances of b2-microglobulin (b2m), a middle
molecule, and p-cresol, a protein-bound solute, in adults on peri-
toneal dialysis as compared to small water-soluble molecules
and (2) to evaluate relations between serum levels and uremic
symptoms.
Methods. We performed a cross-sectional observational
study, including 30 nonanuric peritoneal dialysis patients.
Total, peritoneal, and renal clearances were calculated for urea
nitrogen (60 D), creatinine (113 D), phosphate (96 D), b2m
(11.8 kD), and p-cresol (108 D). All patients were asked to
complete a uremic symptom questionnaire.
Results. Declining total clearances (L/week/1.73 m2) were
measured for urea nitrogen, creatinine, phosphate, b2m, and
p-cresol, respectively: 97.3 ± 4.6, 98.9 ± 6.1, 64.0 ± 3.4, 23.1 ±
2.6, and 17.5 ± 2.3 (Friedman test P < 0.001). Conversely, the
contribution of residual renal function (%) to the respective
solute clearances increased significantly: 31.6 ± 3.2, 51.0 ± 4.0,
42.4 ± 4.0, 68.0 ± 5.4, 61.9 ± 4.6 (Friedman test P < 0.001). The
serum level of p-cresol, but of none of the other solutes exam-
ined, correlated significantly with the symptom score (Pearson
r = 0.48, P = 0.008).
Conclusion. During peritoneal dialysis p-cresol behaves like
b2m, probably due to its protein binding. The total clearance
of both molecules is significantly lower as compared to water-
soluble solutes and mainly depends on residual renal func-
tion. Our data further suggest that protein-bound solutes are
involved in the pathophysiology of uremic symptoms.
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Defining the optimal dose of dialysis for end-stage
renal disease (ESRD) patients treated with peritoneal
dialysis has been among the principle goals of the
nephrology community for more than two decades. The
currently used guidelines suggest that, for continuous am-
bulatory peritoneal dialysis (CAPD), the delivered dose
should be a total Kt/V for urea nitrogen of at least 2.0 per
week and a total clearance of creatinine of at least
60 L/week/1.73 m2 for high and high-average trans-
porters, and 50 L/week/1.73 m2 for low and low-average
transporters [1, 2]. The guidelines were based mainly
on the results of the landmark CANUSA Study [3] and
assume that peritoneal and renal clearances contribute
equally to patient outcome. Subsequent analysis of the
CANUSA data [4], the recent ADEMEX trial [5] and
other studies [6, 7], however, have cast doubt on this as-
sumption and have emphasized the importance of resid-
ual renal function as a predictor of survival. In this
regard, several investigators have stressed the role of
renal function in the maintenance of an adequate fluid
balance [8–11]. However, the superiority of renal over
peritoneal clearance for predicting patient outcome
might also be explained by the finding that the elimination
of some uremic retention solutes depends largely on renal
metabolism and/or secretion at the tubular level, which
cannot be equaled by increasing peritoneal transport.
This is the case for the middle molecule b2-microglobulin
(b2m) as well as for the recently recognized group
of protein-bound solutes [12]. b2m is filtered in the
glomeruli and reabsorbed and degraded in the proximal
tubular cells. Its renal catabolism in a healthy subject was
found to be 150 to 220 mg/day [13]. Protein-bound solutes
are mainly excreted by tubular secretion via the organic
anion transport system of the proximal tubular cells [14].
p-Cresol, a fermentation metabolite of the amino acid ty-
rosine, is regarded as a prototype of the protein-bound
solutes [15]. It has been demonstrated in vitro to in-
hibit several biochemical, biologic, and physiologic func-
tions [15–17]. However, except for one recent report in
hemodialysis patients [18], no correlations with clinical
end points have been presented to date.
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The aim of this cross-sectional observational study was
(1) to investigate the relative contribution of residual re-
nal function to the overall clearances of b2m and p-cresol
in adults on peritoneal dialysis as compared to small
water-soluble solutes and (2) to evaluate the relation
between the serum level of individual retention solutes
and the presence of well-recognized uremic symptoms.
METHODS
Patients and study design
We performed a single-center cross-sectional obser-
vational study. Thirty nonanuric patients with ESRD
treated with peritoneal dialysis at the University Hospi-
tal Leuven were included. Fifteen patients were on auto-
mated peritoneal dialysis (APD) and 15 were on CAPD.
The causes of ESRD were diabetic nephropathy (N = 5),
polycystic kidney disease (N = 4), glomerular disease
(N = 12), tubulointerstitial disease (N = 4), and unknown
etiologies (N = 5). Demographic (age, gender, weight,
and length) and clinical data (dialysis duration, medica-
tion, and comorbidity) were collected by reviewing the
medical records. Comorbidity was scored according to
Davies et al [19] and reported as low, medium or high
grade. For the determination of clearances of urea nitro-
gen, creatinine, phosphate, p-cresol,and b2m a mid-day
blood sample was taken and total amounts of urine and
peritoneal drainage were collected during the preceding
24-hour period, weighed, and sampled. All samples were
stored at −80◦C until analysis. For the evaluation of the
relation between the serum level of individual solutes and
uremic symptoms, the patients were asked to complete a
uremic symptom questionnaire. The study was approved
by the Ethical Committee of the University Hospital
Leuven and informed consent was obtained from all
patients.
Analytic methods
Urea nitrogen, creatinine, and phosphate were mea-
sured by standard laboratory techniques. b2m was
quantitated by rate nephelometry using an Immage In-
strument (Beckman Coulter, Brea, CA, USA). p-Cresol
was analyzed by gas chromatography mass spectrometry
(GC-MS) technology. Five hundred lL of serum was
diluted with 450 lL water. The pH of a 950 lL sample
(diluted serum, urine or dialysis fluid) was adjusted to pH
1 with concentrated H2SO4 and the solution was heated
to 90◦C for 30 minutes. After a cooling down period to
ambient temperature, 50 lL 2,6-dimethylphenol solution
(20 mg/100 mL) was added as internal standard. One
milliliter ethyl acetate was added for the extraction of
p-cresol. The solution was well mixed during 30 seconds
and centrifuged at 3300 rpm for 20 minutes. Then, 500 lL
of the supernatant was dried over anhydrous sodium
sulfate and 100 lL of the resultant sample was trans-
ferred to the GC-MS (Trace GC-MS, Thermofinnigan,
San Jose´, CA, USA) for automatic splitless injection of
0.5 lL. The analytic column used was a 30 m × 0.32 mm
internal diameter, film thickness 1 lm AT5-MS (Alltech,
Deerfield, IL, USA). Helium GC grade was used as a
carrier gas with a constant flow of 1.3 mL/min. The oven
was programmed from 75◦C (isotherm for 5 minutes) to
280◦C with 15◦C per minute. After separation, p-cresol
was identified by MS (Electron Impact full scan mode
from m/z 59 to m/z 590 at 2 scan/second). Quantitative
results were obtained by the internal standard method
and calculated as concentrations (mg/L).
Calculations
Peritoneal, renal, and total clearances normalized to
1.73 m2 body surface area (BSA) (L/week/1.73 m2) were
calculated for all solutes by direct determination from
dialysis fluids, urine and mid-day serum solute concen-
trations. According to the National Kidney Foundation
Dialysis Outcomes Quality Initiative (NKF-K-DOQI)
guidelines [2], residual glomerular filtration rate (GFR)
was estimated by calculating the arithmetic mean of renal
urea nitrogen and creatinine clearance and expressed in
mL/min/1.73 m2. Peritoneal, renal, and total Kt/V were
calculated only for urea nitrogen (Kt/VUN). BSA was
estimated by the Du Bois and Du Bois method [20]. The
distribution volume of urea nitrogen (V) was assessed
by the Watson, Watson, and Batt formula for total body
water [21]. Protein nitrogen appearance, normalized
to body weight (nPNA) was calculated according to
Bergstro¨m, Heimburger, and Lindholm [22].
Uremic symptom score
A uremic symptom score was developed, using a previ-
ously described dyspepsia questionnaire [23–25] with the
addition of 12 symptoms. Each patient was asked to grade
the intensity (0, absent; 1, mild; 2, relevant; 3, severe and
interfering with daily activities) of 20 different symptoms
(Table 1). As indicated in the table, the total sum of scores
(Stot) was calculated as well as the subtotals for three dif-
ferent symptom classes: gastrointestinal symptoms (Sgi),
neurological symptoms (Sneur), and itching (Sskin).
Statistics
Data are expressed as mean ± SEM. Differences be-
tween APD and CAPD were evaluated using unpaired
Student t test or Mann-Whitney U test for continuous
data and chi-square test of association for categorical data
where appropriate. For paired comparisons of different
solute clearances, Friedman test with post hoc analysis
was used. Pearson correlation coefficients were calcu-
lated to assess possible associations between clearances,
parameters of renal function, serum solute concentra-
tions, and uremic symptom scores. P values less than 0.05
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Table 1. Uremic symptom questionnaire
0 1 2 3
1. Epigastric discomfort worsening 0 0 0 0
with food intake
2. Epigastric pain 0 0 0 0
3. Early satiety 0 0 0 0
4. Postprandial fullness 0 0 0 0
5. Bloating 0 0 0 0
6. Nausea 0 0 0 0 Sgi (0–33)
7. Vomiting 0 0 0 0
8. Belching 0 0 0 0
9. Epigastric burning 0 0 0 0
10. Hiccup 0 0 0 0
11. Decreased appetite 0 0 0 0 Stot (0–60)
12. Sleeping disorders 0 0 0 0
13. Fatigue 0 0 0 0
14. Erratic memory 0 0 0 0
15. Concentration disturbances 0 0 0 0
16. Drowsiness 0 0 0 0 Sneur (0–24)
17. Headache 0 0 0 0
18. Cramps 0 0 0 0
19. Restless legs 0 0 0 0
20. Itching 0 0 0 0 Sskin (0–3)
Indicate the intensity of each of the following symptoms during the previous
3 months 0 = absent 1 = mild 2 = relevant 3 = severe and interfering with daily
activities.
Example of the uremic symptom questionnaire. In the table, total sum of scores
and the subtotals according to three symptom classes are indicated. The ranges
of possible scores are indicated between parentheses.
were considered significant. The SAS version 8.02 (SAS
Institute, Cary, NC, USA) software program was used for
the statistical analysis.
RESULTS
Patient characteristics
Patient characteristics are summarized in Table 2.
Mean age was 52.0 ± 3.0 years. Mean duration of dial-
ysis at the time of the study was 16.2 ± 2.0 months.
Mean body weight was 66.5 ± 2.2 kg and mean BSA was
1.75 ± 0.04 m2. Mean 24-hour urine output was 1009 ±
120 mL. Mean 24-hour peritoneal drainage was 11658 ±
553 mL. There were no statistically significant differences
between APD and CAPD patients in any of the observed
parameters. Renal diagnoses were equally distributed be-
tween the two groups. There were no differences in the
use of diuretics, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin II receptor blockers, other antihy-
pertensives, and nonsteroidal anti-inflammatory drugs.
Peritoneal dialysis adequacy
No significant differences were found between APD
and CAPD for mid-day serum levels of urea nitrogen,
creatinine, phosphate, and b2m. Serum p-cresol was sig-
nificantly lower in CAPD than in APD patients (P =
0.0049). Peritoneal, renal, total Kt/VUN values, and GFR
were not different between the two groups (Table 3).
There were no differences between APD and CAPD
in peritoneal clearances of urea nitrogen, creatinine,
and phosphate. Conversely, peritoneal clearances of b2m
(2.83 ± 0.21 vs. 6.24 ± 0.83, P = 0.003) and p-cresol
(3.60 ± 0.37 vs. 5.91 ± 0.69, P = 0.020) were significantly
lower in APD than in CAPD patients. No differences in
renal clearances between APD and CAPD were observed
for any of the solutes studied (data not shown).
Total and separated (peritoneal and renal) clearance
values for the 30 patients are summarized in Table 4 and
illustrated in Figure 1. Data are also expressed as percent-
ages of the overall clearances. Declining total clearances
were measured for urea nitrogen, creatinine, phosphate,
b2m, and p-cresol, respectively (Friedman test P < 0.001).
Conversely, the contribution of residual renal function
to the respective solute clearances increased significantly
(Friedman test P < 0.001).
Serum levels of b2m and p-cresol correlated negatively
with 24-hour urine volume (r = −0.46, r = −0.15, re-
spectively), renal weekly Kt/VUN (r = −0.42, r = −0.27,
respectively) and GFR (r = −0.49, r = −0.32, respec-
tively). However, statistical significance was reached only
for b2m. Peritoneal clearance values of urea nitrogen,
creatinine, and phosphate were inversely correlated with
their respective renal clearances (r = −0.43, P = 0.019;
r = −0.32, P = 0.082; and r = −0.43, P = 0.024, respec-
tively). This relationship was absent for b2m (r = −0.19,
P = 0.342) and p-cresol (r = 0.09, P = 0.625).
Uremic symptom score
For the total group of 30 patients mean Stot was 7.6 ±
1.2. Sgi, Sneur, and Sskin amounted to 2.63 ± 0.78, 4.27 ±
0.50, and 0.73 ± 0.16, respectively. There were no signifi-
cant differences between APD and CAPD for any of the
score sums, although there was a trend to lower scores in
CAPD patients.
Of all solutes, only the serum level of p-cresol corre-
lated significantly with Sgi (r = 0.47, P = 0.008), Sskin
(r = 0.38, P = 0.041), and Stot (r = 0.48, P = 0.008)
(Fig. 2). There were no significant differences in symptom
scores between patients with low, medium, and high grade
comorbidity.
DISCUSSION
Our study, comprising 30 ESRD patients treated with
peritoneal dialysis, shows that the total and peritoneal
clearances of b2m, p-cresol, and phosphate are signif-
icantly lower as compared to the clearances of the
reference uremic retention solutes urea nitrogen and cre-
atinine (Table 4) (Fig. 1). For b2m this observation is
not surprising, since the high molecular weight of the
solute (11815 D) hampers its diffusive and convective
transport through the pores of the peritoneal membrane
[26–28]. The findings are in accordance with earlier stud-
ies in children [29, 30] and adults on peritoneal dialysis
[31]. The low clearances of p-cresol (108 D) represent a
new finding. They are not unexpected, however, given the
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Table 2. Patient characteristics
All APD CAPD P value
Number 30 15 15 —
Age years 52.0 ± 3.0 52.5 ± 5.1 51.5 ± 3.5 0.805
Male/female 16/14 8/7 8/7 1.000
Dialysis duration months 16.2 ± 2.0 19.7 ± 3.3 12.6 ± 2.0 0.070
24-hour urine output mL 1009 ± 120 1096 ± 197 922 ± 140 0.525
24-hour peritoneal drainage mL 11658 ± 553 12607 ± 832 10709 ± 669 0.092
24-hour ultrafiltration volume mL 1308 ± 339 874 ± 355 1742 ± 569 0.206
Body weight kg 66.5 ± 2.2 65.6 ± 3.5 66.5 ± 2.8 0.566
Body surface area m2 1.75 ± 0.04 1.74 ± 0.06 1.76 ± 0.05 0.789
Normalized protein nitrogen appearance g/kg/day 2.06 ± 0.10 2.01 ± 0.12 2.11 ± 0.16 0.886
Comorbidity (low/medium/high grade) 15/11/4 8/4/3 7/7/1 0.390
Use of phosphate binders (yes/no) 16/4 13/2 13/2 1.000
Use of vitamin D (yes/no) 11/19 4/11 7/8 0.256
Abbreviations are: APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis.
Date are expressed as mean ± SEM. Differences between APD and CAPD were evaluated using unpaired Student t test or Mann-Whitney U test for continuous
data and chi-square test of association for categoric data where appropriate.
Table 3. Mid-day serum concentrations, Kt/VUN, GFR
All APD CAPD P value
Number 30 15 15 —
UN mg/dL 110.6 ± 4.7 111.2 ± 6.2 101.1 ± 7.3 0.712
Cr mg/dL 7.18 ± 0.39 7.27 ± 0.44 7.08 ± 0.66 0.499
P mg/dL 4.46 ± 0.21 4.72 ± 0.34 4.20 ± 0.24 0.318
p-cresol mg/L 37.2 ± 3.2 46.5 ± 4.8 27.9 ± 2.5 0.005
b2m mg/L 18.1 ± 1.4 17.8 ± 1.5 18.4 ± 2.4 0.637
Peritoneal Kt/VUN 1.94 ± 0.16 1.76 ± 0.16 2.13 ± 0.27 0.281
Renal Kt/VUN 0.88 ± 0.10 0.87 ± 0.14 0.89 ± 0.15 0.853
Total KT/VUN 2.83 ± 0.16 2.63 ± 0.11 3.02 ± 0.30 0.453
GFR mL/min/1.73 m2 4.17 ± 0.47 4.03 ± 0.63 4.32 ± 0.72 0.789
Abbreviations are: APD, automated peritoneal dialysis; CAPD, continuous
ambulatory peritoneal dialysis; GFR, glomerular filtration rate; UN, urea nitrogen; Cr,
creatinine; P, phosphate; b2m, b2-microglobulin.
Data are expressed as mean ± SEM. Differences between APD and CAPD were
evaluated using Mann-Whitney U test. Total p-cresol was significantly lower in CAPD
than in APD.
molecules’ protein binding, which was demonstrated to
be virtually complete in healthy controls and about 90%
in ESRD patients [32]. The protein binding also explains
the limited removal of the solute by low- and high-flux
hemodialysis, as demonstrated by others [32, 33].
Our clearance data demonstrate that the elimination of
b2m and p-cresol depends largely on residual renal func-
tion (Table 4) (Fig. 1). The importance of renal elimina-
tion is further stressed by the inverse relationship found
between serum levels of both molecules and parameters
of renal function (24-hour urine volume, renal Kt/VUN,
and GFR). For p-cresol this relationship lacks statisti-
cal significance, which can probably be attributed to the
fact that the generation rate of the molecule, in con-
trast to that of b2m [34–36], can vary substantially within
and between individuals. The amount of ingested protein
escaping small intestinal digestion and absorption, the
characteristics of the bacterial flora and the colonic tran-
sit time were all shown to influence p-cresol generation
[37–39]. Variations of these factors might obscure the re-
lationship between serum levels of the solute and its renal
elimination.
Peritoneal clearance values of urea nitrogen, creati-
nine, and phosphate were inversely correlated with their
respective renal clearances, which was not the case for
b2m and p-cresol. This observation further underlines
the importance of residual renal function for the elimina-
tion of the latter molecules, since a loss of renal clearance
seems not to be compensated by an increase in peritoneal
clearance.
Several recent studies indicate the value of residual
renal function as a predictor of patient survival in peri-
toneal dialysis patients [4–7]. This has been explained by
its role in the maintenance of an adequate fluid balance
[8–11]. In view of our findings, the conservation of renal
elimination mechanisms other than glomerular filtration
[13, 14] might contribute substantially to the explanation
of residual renal function as an outcome predictor.
The finding of low clearance values of phosphate (96 D)
is in accordance with earlier reports illustrating the mid-
dle molecule characteristics of the solute [40–42]. Several
explanations for this particular behavior have been for-
mulated. First, due to its hydrophilic characteristic, the
phosphate molecule is surrounded by an aqueous cover.
Moreover, up to 40% of the circulating phosphate has
been shown to be a component of sodium, calcium, and
magnesium salts [40]. Finally, phosphate is mainly dis-
tributed in the intracellular space with a slow intra- and
extracellular solute transfer rate [43].
We found significant differences in peritoneal clear-
ances of b2m and p-cresol between APD and CAPD.
This observation corroborates the results of a recent
study, which showed that in contrast to small water-
soluble molecules, the peritoneal clearance of b2m
depends mainly on the total dwell hours of peritoneal
dialysis and not on the number of exchanges of dialysis
fluid [31]. Moreover, although not statistically significant,
the 24-hour ultrafiltration volume was higher in CAPD
than in APD patients, which might have contributed to a
greater solute removal by convection in the former. On
the other hand, the duration of dialysis at the time of our
study was shorter in the CAPD patients (not statistically
significant). This may have biased our results, since the
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Table 4. Peritoneal, renal, and total clearances
Urea nitrogen Creatinine Phosphate b2-microglobulin p-cresol
Molecular weight daltons 60 113 96 11815 108
Total clearance L/week/1.73 m2 97.3 ± 4.6 98.9 ± 6.1 64.0 ± 3.4a,b 23.1 ± 2.6a,b,c 17.5 ± 2.3a,b,c
Peritoneal clearance L/week/1.73 m2 66.6 ± 4.8 45.3 ± 3.5a 35.9 ± 2.7a 4.66 ± 0.54a,b,c 4.75 ± 0.44a,b,c
Peritoneal clearance % of total clearance 68.4 ± 3.2 49.0 ± 4.0a 57.6 ± 4.0a 32.0 ± 5.4a,b,c 38.1 ± 4.6a,c
Renal clearance L/week/1.73 m2 30.7 ± 3.5 53.6 ± 6.2a 28.1 ± 3.6b 18.4 ± 2.7a,b,c 12.7 ± 2.2a,b,c
Renal clearance % of total clearance 31.6 ± 3.2 51.0 ± 4.0a 42.4 ± 4.0a 68.0 ± 5.4a,b,c 61.9 ± 4.6a,c
Data are expressed as mean ± SEM. Differences were evaluated using Friedman test with post hoc analysis.
aP < 0.05 vs. urea nitrogen; bP < 0.05 vs. creatinine; cP < 0.05 vs. phosphate.
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Fig. 1. Peritoneal, renal, and total clearances of urea nitrogen (UN),
creatinine (Cr), phosphate (P), b2-microglobulin (b2m), and p-cresol.
Mean values are illustrated.
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Fig. 2. Total sum of scores (Stot) vs. total serum p-cresol (mg/L). Pear-
son correlation coefficient (r) and P value are indicated.
peritoneal membrane restriction coefficient for macro-
molecules has been demonstrated to increase in relation
to the years on peritoneal dialysis treatment [30, 44].
Serum levels of p-cresol were significantly lower in
CAPD than in APD patients. This finding most proba-
bly reflects the differences in peritoneal clearance of the
molecule, since no differences between the two groups
were seen in parameters of renal function (24-hour urine
output, renal Kt/VUN, or GFR) or in dietary protein
intake (nPNA).
An interesting finding of our data is the positive cor-
relation between serum levels of p-cresol and a uremic
symptom score, based on a validated dyspepsia question-
naire [23–25]. To our knowledge, this is the first evidence
of a clinical end point related to the protein-bound reten-
tion product in peritoneal dialysis patients. One might
argue that this relation is self-evident, since p-cresol is
just one of the numerous retention solutes in uremia and
might play the role of “innocent bystander.” However,
p-cresol was the only of the five toxins studied revealing
a significant correlation with the symptom score. More-
over, there was a trend to lower symptom scores in the
CAPD patients in conjunction with lower serum levels
and higher peritoneal clearances of p-cresol as compared
to the APD patients. These observations further suggest
that protein bound solutes play a role in the pathophysi-
ology of uremic symptoms.
We recognize that the serum levels of p-cresol found
by our laboratory are higher than most other values
reported in the literature [45, 46]. A possible explanation
for this discrepancy lies in the sample preparation, which
consists essentially of a deproteinization and an extrac-
tion step. In addition to acid deproteinization, which is
applied in most other studies, we used heat denaturation.
It is not excluded that the high temperature used in this
setting not only deproteinizes the serum but, in addition,
provokes hydrolysis of circulating conjugates of p-cresol
(p-cresylsulfate and p-cresylglucuronide). Although dif-
ferences in concentration measurements would proba-
bly have no impact on clearance calculations, further
research is needed to elucidate this topic.
CONCLUSION
Our data show clear evidence for the middle molecule
characteristics of the protein-bound solute p-cresol dur-
ing peritoneal dialysis. As for b2m, its total and peritoneal
clearances were shown to be lower than those of the
small water-soluble solutes urea nitrogen and creatinine.
Moreover, the importance of residual renal function in
the elimination of b2m and p-cresol was demonstrated.
Finally, our study is supportive for the involvement of
protein-bound solutes in the pathophysiology of uremic
symptoms.
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